Graphite Bio Inc Stock

$20.87

9.28% today

Nasdaq, Apr 04, 08:49 pm CET

ISIN

US38870X1046

Symbol

LENZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Graphite Bio Inc Stock price

$23.00

-64.56 73.73% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

-2.51 9.84%

ISIN

US38870X1046

Symbol

LENZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$633.49m
Enterprise Value	$425.73m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	3.10
Dividend yield	0.00%
Last dividend (FY24)	$7.21
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-58.61m
Cash position	$209.14m
EPS (TTM) EPS	$-4.77
P/E forward	negative
P/S forward	83.05
EV/Sales forward	55.82
Short interest	17.99%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Graphite Bio Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Graphite Bio Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Graphite Bio Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Graphite Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.06 0.06	99% 99% -
Gross Profit	-0.06 -0.06	99% 99% -
- Selling and Administrative Expenses	29 29	6% 6% -
- Research and Development Expense	30 30	7% 7% -
EBITDA	-59 -59	14% 14% -
- Depreciation and Amortization	0.06 0.06	99% 99% -
EBIT (Operating Income) EBIT	-59 -59	20% 20% -
Net Profit	-50 -50	60% 60% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Graphite Bio Inc Stock News

Positive

Seeking Alpha

●

8 days ago

LENZ Therapeutics Stock Is Attractive Before PDUFA

LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, ta...

Neutral

Seeking Alpha

●

16 days ago

LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanza...

Neutral

GlobeNewsWire

●

16 days ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025

More Graphite Bio Inc News

Company Profile

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Evert Schimmelpennink
Employees	42
Founded	2017
Website	www.lenz-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now